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Abstract
Background: Seladin-1 overexpression exerts a protective mechanism against apoptosis. Seladin-1 mRNA is variably 
expressed in normal human tissues. Adrenal glands show the highest levels of seladin-1 expression, which are 
significantly reduced in adrenal carcinomas (ACC). Since up to now seladin-1 mutations were not described, we 
investigated whether promoter methylation could account for the down-regulation of seladin-1 expression in ACC.
Methods: A methylation sensitive site was identified in the seladin-1 gene. We treated DNA extracted from two ACC 
cell lines (H295R and SW13) with the demethylating agent 5-Aza-2-deoxycytidine (5-Aza). Furthermore, to evaluate the 
presence of an epigenetic regulation also 'in vivo', seladin-1 methylation and its mRNA expression were measured in 9 
ACC and in 5 normal adrenal glands.
Results: The treatment of cell lines with 5-Aza induced a significant increase of seladin-1 mRNA expression in H295R 
(fold increase, F.I. = 1.8; p = 0.02) and SW13 (F.I. = 2.9; p = 0.03). In ACC, methylation density of seladin-1 promoter was 
higher (2682 ± 686) than in normal adrenal glands (362 ± 97; p = 0.02). Seladin-1 mRNA expression in ACC (1452 ± 196) 
was significantly lower than in normal adrenal glands (3614 ± 949; p = 0.01).
Conclusion: On this basis, methylation could be involved in the altered pattern of seladin-1 gene expression in ACC.
Background
Seladin-1 (Selective Alzheimer disease indicator 1, sela-
din-1) gene (chromosome 1p33-31.1), firstly identified in
neuronal cells [1], codes for the cholesterol synthesizing
enzyme (3-beta-hydroxysterol delta-24-reductase,
DHCR24) and show high homology to the Diminuto like
protein, a cell elongation factor described in Arabidopsis
thaliana [2]. The expression of seladin-1 mRNA and pro-
t e i n  i s  d o w n - r e g u l a t e d  i n  b r a i n  r e g i o n s  a f f e c t e d  b y
Alzheimer's disease [1,3].
The involvement of seladin-1 in human cancers was
recently investigated. Seladin-1 mRNA expression is acti-
vated in response to Ras expression, showing features of a
potential tumor suppressor involved in the oncogenic sig-
nalling mediated by Ras/p53 [4]. The ablation of this gene
in the presence of oncogenic and oxidative stress results
in cell transformation. With regard to the enzymatic
activity of seladin-1 involving cholesterol synthesis, it is
known that some cancers show increased cholesterol
content compared to normal tissues. The latter finding
was accompanied by an enhanced anti-oxidant activity
and consequent resistance to oxidative stress, thus con-
ferring selective growth advantage to tumor cells [5,6].
The inhibition of caspase 3 and a key role in cholesterol
synthesis represent the two main biological functions of
seladin-1. In the latter case, it is still unclear whether the
effects of seladin-1 are an indirect consequence of the
modulation of intracellular cholesterol, which has well
documented protective effects in vitro and in vivo [7-11].
Seladin-1 was investigated in prostate [12-14], ovary
[15], bladder [16] and breast cancer [17], in melanoma
[18] and pituitary adenomas [19].
Adrenal gland is the human tissue with the highest lev-
els of expression of seladin-1 [1] whereas mRNA levels
are markedly reduced in adrenal carcinomas, reaching
the lowest levels in advanced disease (stages III-IV) [20].
Nevertheless, the demonstrated antiapoptotic role of
seladin-1 [4,21] mainly due to its H2O2 scavenging activ-
ity [22] may give rise to difficulties in the meaning of sela-
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din-1 downregulation in adrenal cancer. However,
increased proliferation rate in tumoral cells may lead to
increased apoptotic death [20]. It has been also reported
that seladin-1 mRNA expression in cultured cells is mod-
ulated by ACTH [20,23], suggesting that its down-regula-
tion in adrenal cancer may be due to a reduced expression
of its receptor, as a marker of loss of differentiation.
In the hypothesis that epigenetic modifications may
influence differential expression of seladin-1 in adrenal
cancer we analyzed whether methylation could be
regarded as a mechanism of seladin-1 regulation in
human adrenal cancer cell lines and tissues.
Methods
Cell cultures and treatment
Two adrenal gland-derived cell lines, H295R and SW13,
were used for this study . Cell lines were maintained at
37°C in a 95% air and 5% CO2 fully humidified environ-
ment in a culture medium consisting of a 1:1 (vol/vol)
mixture of DMEM/F-12 with 10% FBS, 2 mm glutamine,
100 U/ml penicillin, and 100 μg/ml streptomycin. For
H295R, medium was enriched with a mixture of insulin/
transferrin/selenium. Cells were plated in duplicate and
treated with 5 μM of 5-Aza-2-deoxycytidine (5-Aza) for
1, 3 and 6 days. Three separate experiments were per-
formed in the same experimental conditions and results
w e r e  c a l c u l a t e d  a s  t h e  m e a n  o f  s u c h  r e p l i c a t e s .  R N A
extraction was performed with Rneasy MiniKit Qiagen®
columns, while DNA was obtained by using QIAamp
DNA Mini Kit (Qiagen, Milan, Italy).
Patients
A total of 14 samples, collected in the Surgical Depart-
ment of the Azienda Ospedaliera Careggi, Florence, with
the approval of the local Ethics Committee, included 9
adrenal carcinomas and 5 normal adrenal from patients
undergoing nephrectomy for renal cancer. Informed con-
sent was obtained from each patient. All samples were
accurately examined by an expert pathologist to prevent
contaminations from contiguous tissues. Samples were
immediately snap frozen in liquid nitrogen until acid
nucleic extraction. For RNA extraction, tissues were dis-
rupted by homogenisation in 600 μl of guanidine isothio-
cyanate containing lysis buffer and then processed with
Rneasy MiniKit Qiagen® columns. Genomic DNA was
extracted from neoplastic tissues using DNeasy Tissue
Kit (Qiagen Milan, Italy).
Reverse transcription and quantitative real-time PCR
Total RNA (200 ng) was reverse transcribed in a 40 μl
reaction mixture containing TaqMan RT buffer 1×, 5.5
mM MgCl2, 500 μM each dNTPs, 2.5 μM random hex-
amers, 0.4 U/μl RNase inhibitors and 1.25 U/μl Multi-
Scribe reverse transcriptase. The profile of the one step
reverse transcription reaction was 10 min at 25°C, 30 min
at 48°C and 2 min at 95°C. The PCR reaction was per-
formed with 25 ng cDNA, in a reaction mix containing
300 nM of forward primer, 900 nM of reverse primer, 12.5
μl Universal Master Mix and 200 nM of each fluorescent
probe. Plates were treated 2 min at 50°C, 10 min at 95°C
and then submitted to 40 cycles of amplification at 95°C
for 15 s, 60°C for 60 s in the ABI Prism 7700 Sequence
Detector PE Applied Biosystems (Foster City, CA, USA).
Seladin-1 mRNA expression was evaluated with relative
quantitative RT-PCR using primers and probe as previ-
ously reported [20]. The integrity of total RNA was veri-
fied in all samples with Agilent 2100 bioanalyzer and as
reference gene the evaluation of GAPDH mRNA expres-
sion was performed by using the Pre-Developed TaqMan
Assay Reagent, GAPDH endogenous control kit from
Applied Biosystems.
Methylation specific PCR
Methyl Primer Express® Software v1.0 (Applied Biosys-
tems, Foster City, CA, USA) was used to evaluate methy-
lation-sensitive sites in seladin-1 sequence from -4384 bp
and +1826 bp. The region from -4384 bp to -1150 did not
reveal any CpG island. In the remaining sequence, we
identified a large 1786 bp long CpG island from -868 bp o
+918 bp. We analyzed two separate sequences in this
region by MSP: the first, from -404 bp to -136 bp did not
evidence methylation sensitive site (data not shown). In
the second region, partially comprising exon1 and the
transcription starting site (Figure 1; see also Ref [4] for
more sequence details) we selected a primer set for meth-
yla t ed f orm wit h t he  f o llo wi ng seq ue nc es:  F2 m et h 5' -
CGGGTTGTGGGTTATAGGC-3', localised at -97 and
R2 meth 5'-ACGAACACCCAACGCTAATAAAT-3' at
+81 nucleotide from the same site (amplicon length 202
bp). The unmethylated form of the same sequence was
amplified using the primers: F2unmeth 5'-TTGTGGGT-
TATAGGTGTAGAGT-3' at -93 nucleotide from transla-
tion start site and R2unmeth 5'-CCAAACACACAC
ATAATAATAAA-3' at +141 (amplicon length of 258 bp).
DNA from cell lines and tissue samples (500 ng) was
submitted to bisulphite modification using EpiTect
Bisulfite Kit (Qiagen, Milan, Italy) following manufac-
turer's protocol. For each treatment, CpG Genome Uni-
versal Methylated and Unmethylated DNA (Chemicon
International Inc, USA) were used as positive and nega-
tive controls to confirm specificity of methylation specific
PCR (MSP). After bisulphite treatment, DNA was imme-
diately submitted to PCR analysis.
MSP was performed submitting modified DNA to 94°C
for 5 min and 50 cycles at the sequent conditions: 94°C
for 30 sec, 58°C for 30 sec, 72°C for 30 sec and a final hold
to 72°C for 10 min. PCR product were then resolved in a
2% agarose gel.Simi et al. BMC Cancer 2010, 10:201
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Quantitative methylation specific PCR for methylation 
analysis
Q-MSP was performed to confirm qualitative results
using a real time RT-PCR assay. Quantitative analysis was
performed on RotorGene™3000 (Corbett Research, Aus-
tralia) in a final volume of 10 μl with Quantitect Probe
PCR Master Mix 2× (Qiagen, Milan, Italy), primers 600
nmol/l and probe 200 nmol/l and 1 μl of modified DNA.
Specificity of the assay was achieved using the same
primers for the methylated DNA together with an inter-
nal probe selected by PrimerExpress software (Applied
Biosystems, Foster City, CA, USA) with sequence: 5'-TTG
GCG GTA GTG ATA G-3', localised at -56 nucleotide
from transcription start site and labelled with FAM. PCR
conditions were: 95°C for 15 min, 55 cycles at 95°C for 15
sec and 60°C for 60 sec. In all samples β-Actin DNA was
analysed after bisulfite treatment using primers and
probe previously described [24] to perform relative quan-
tification. As for mRNA analysis, changes in DNA methy-
lation pattern were evaluated considering the treated/
untreated ratio. The same protocol was used to perform
seladin-1 quantification in normal adrenal gland samples
and carcinomas.
Pyrosequencing analysis
Analysis of sequences after bisulfite treatment was per-
f o r m e d  b y  P y r o s e q u e n c i n g ™  ( P y r o M a r k  I D  S y s t e m ,
Biotage, Sweden) technology. Primers selected to per-
form amplification were designed using PyroQ-CpG™
Software (Biotage, Sweden) and were: FW 5'-GTT TGA
AGG GGT TGG AGT-3' and RV 5'-CTC ACC TAC TTC
TAA ATA TCC C-3'. Amplification has been performed
using one hundred nanograms of total DNA in a PCR
reaction mix in 50 μl final volume. Samples were dena-
tured for 9 min at 94°C followed by 40 cycles of amplifica-
tion at 94°C for 1 min, 55°C for 1 min and then 72°C for
90 sec, in a Gene Amp 9700 Thermal Cycler (Applied
Biosystems, Milan, Italy). Thirty μl of PCR product were
Figure 1 Schematic representation of CpG island in seladin-1 promoter and methylation status in H295R and SW13 cell lines. (Panel A) The 
large CpG island includes the translation start codon (ATG), spanning from -868 bp to +918 bp. The arrows F1 and R1 indicate primers which did not 
evidence any methylation sensitive sites. F2 and R2 are primers used for MSP and Q-MSP analysis. (Panel B) Methylation specific PCR performed in 
H295R and SW13 cell lines. Primers for methylated (upper gel) and unmethylated DNA (lower gel) recognized in both cell lines corresponding meth-
ylated and unmethylated seladin-1 promoter sequences. After 6 days of treatment with 5-Aza (+5Aza) we observed a reduction of methylated form 
in both cell lines in comparison to controls (-5Aza). Conversely, the intensity of bands corresponding to unmethylated DNA increased in intensity, con-
firming the demethylation of corresponding sequences. (NTC = no template control, MW = molecular weight marker, M = cell line methylated DNA, 
UM = cell line unmethylated DNA).
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used for immobilization by streptavidin sepharose beads
(Streptavidin Sepharose™ High Performance, GE Health-
care Bio-Science AB, Sweden) and then incubation at
95°C for 5 minutes of single-stranded DNA with the
sequencing primer, a biotynilated reverse primer with the
same sequence used in PCR, has been performed.
Statistical analysis
Statistical analysis was carried out using the SPSS soft-
ware package (SPSS INC, Chicago, IL). The Wilcoxon
Rank-Sum test for paired samples was used to test differ-
ences in control cells versus cells treated with demethy-
lating 5-Aza, while Kolmogorov-Smirnov test data was
used to evaluate differences between adrenal carcinomas
and normal adrenal glands. Differences with p < 0.05
were considered statistically significant.
Results
Methylation specific PCR (MSP) of methylation-sensitive 
promoter region
DNA extracted from H295R and SW13 cell lines was sub-
mitted to MSP with primers targeting methylated and
unmethylated alleles, alternatively. As reported in Figure
1, in both cases amplification generated amplicons with
the expected size, suggesting that methylation of seladin-
1 promoter is in hemi-methylated status in both cell lines.
When cell lines were submitted to 5-Aza treatment, MSP
revealed a reduction of the intensity of the band corre-
sponding to methylated DNA in comparison to untreated
cell lines, which was paralleled by an increase of amplifi-
cation products when primers for unmethylated DNA
were used (Figure 1, Panel B).
Quantitative methylation specific PCR (qMSP) of seladin-1 
promoter methylation in vitro
We assessed the methylation and expression patterns of
seladin-1 in adrenal cell lines submitted to the same pro-
tocol of treatment with 5-Aza. Results obtained from
qMSP in DNA extracted from treated cell lines (Figure 2,
panel A) indicated that the levels of DNA methylation
progressively decreased in both cell lines under treat-
ment, with the maximal effect of 5-Aza on DNA methyla-
tion observed after six days. Apparently the effect was
more evident on SW13, probably due to the higher prolif-
eration rate of this line in comparison to H295R cells. The
same treatment induced a progressive up-regulation of
seladin-1 mRNA expression. Once again the positive
effect appeared more evident for SW13 cells, whereas the
induction on seladin-1 expression in H295R cells was less
marked (Figure 2, panel B).
Relationship between seladin mRNA expression and 
methylation pattern in adrenal tissues
To test whether seladin-1 could be epigenetically regu-
lated also 'in vivo', promoter methylation and its mRNA
expression were measured in 9 adrenal carcinomas and in
5 normal adrenal glands. For seladin-1 mRNA, our
results confirmed those previously reported [20]: in adre-
nal carcinomas seladin-1 mRNA (1434 ± 192) was signifi-
cantly lower than in normal adrenal glands (3433 ± 826; p
= 0.01) (Figure 3). Conversely, DNA methylation evi-
denced a statistically significant (p = 0.02) increase in car-
cinoma samples (2633 ± 707) compared to normal tissues
(362 ± 97).
The presence of differential patterns of methylation
between DNA from adrenal carcinomas and normal
adrenal glands was confirmed with pyrosequencing. An
example of respective pyrograms is reported in Figure 4.
Discussion
Epigenetic events, such as DNA methylation, are crucial
in establishing the correct pattern of gene expression.
Disruption of this program leads to an aberrant mRNA
transcription and potential loss of anti-cancer check-
points.
The role of seladin-1 in cancer is still unclear, probably
due to the multiple roles of this gene in regulating cell
Figure 2 Effects of 5 μM 5-Aza treatment on H295R and SW13cell 
lines. (Panel A) Decrease of seladin-1 promoter methylation in DNA 
from the two cell lines. Results were expressed as fold decrease in com-
parison to T0 values. (Panel B) Increase of seladin-1 mRNA expression 
in the same cell lines after treatment with 5-Aza. Results were ex-
pressed as fold increase in comparison to T0 values.
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functions. However, a thorough analysis of seladin-1 role
in oncogenesis and oxidative stress indicated that its
expression is involved in the regulation of Ras-induced
transformation and senescence in human and rodent cells
[4]. Apparently, seladin-1 exerts its protective effects
against oxidative stress following two independent ways.
Seladin-1 is up-regulated as a response to acute oxidative
stress, with a cholesterol-dependent mechanism, but is
down-regulated upon chronic exposure to oxidative
stress. However, also the reduction of seladin-1 expres-
sion appears involved in a prosurvival strategy due to its
interaction with p53 status and function, as recently dem-
onstrated [25]. The initial consideration that adrenal
glands show very high mRNA expression levels of sela-
din-1 [1] and that adrenal carcinomas show a significant
reduction of seladin-1 mRNA [20], has prompted a
deeper analysis of this gene expression in adrenal cancer.
On this basis, the definition of the regulation of seladin-1
expression seems to be crucial for the comprehension of
the mechanisms underlying its downregulation in
tumoral tissues.
In the present study we demonstrated for the first time
the presence of a functionally active CpG island in the
regulatory sequence of Seladin-1 gene. Qualitative and
quantitative methylation specific PCR clearly indicated
that in the adrenal cancer cell lines H295R and SW13 the
CpG island is densely methylated and that the treatment
with the 5-Aza was able to decrease DNA methylation. In
the same experiments we demonstrated that the expres-
sion of seladin-1 mRNA could be directly related to the
altered pattern of promoter methylation since exposure
of adrenal cell lines to 5-Aza was associated to a signifi-
cant induction of Seladin-1 mRNA expression in SW13
and H295R lines, even if the effects of 5-AZA on H295R
methylation is apparently less evident than in SW13. This
difference could refer to the different proliferation rate of
the two cell lines. The higher proliferative rate of SW13
can explain the major effect of 5-AZA in reducing DNA
methylation, since the incorporation of citosine analogue
is much more elevated in cells with a shorter duplication
time. After 6 days of treatment, methylation in SW13 is
close to 0% and the effect of Seladin-1 mRNA expression
is maximal. Conversely, H295R tend to proliferate more
slowly and after 6 days 30% of their DNA is still methy-
lated and the gain of mRNA expression, even if signifi-
cantly increased, is less intense than in SW13.
In addition, we experienced also a different effect of the
demethylating agent on the respective proliferation rate.
5-Aza treatment induced a reduction of cell growth in
H295R that reaches a 50% inhibition after a 6-days treat-
ment, as previously reported [26,27], whereas the reduc-
tion of cell line growth in SW13 was only 15% in
comparison to controls. Therefore, the discrepancy of the
effects in the two cell lines is probably connected to their
ability to grow in normal cultural conditions and under 5-
AZA treatment.
After these preliminary indications obtained 'in vitro',
we tried to confirm the presence of an epigenetic control
of seladin-1 expression also in 'ex vivo' samples. Real time
analysis performed on the same promoter region in DNA
of adrenal carcinomas, adenomas and normal glands
showed an inverse relationship between methylation of
seladin-1 and its expression. In particular hypermethyla-
tion was associated to reduced seladin-1 expression levels
Figure 3 Seladin-1 mRNA expression (panel A) and DNA methylation (panel B) in normal adrenal glands (n = 5) and carcinomas (n = 9).
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Figure 4 Examples of two pyrograms showing a different pattern of methylation in one normal adrenal gland (upper panel) and one adre-
nal carcinoma (lower panel).Simi et al. BMC Cancer 2010, 10:201
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in adrenal cancer compared to normal adrenal gland and
adenomas. No significant difference between adenomas
and normal adrenal glands was evidenced. Thus, at least
in adrenal carcinomas, hypermethylation could account
for the reduction of mRNA expression [20].
To our knowledge, this is the first evidence that the pat-
tern of expression of seladin-1 may be regulated by a dif-
ferential methylation status of the promoter region of this
gene, even if the transcription activation after 5-Aza is
not a final confirmation of a direct epigenetic regulation
on the gene itself. In fact an indirect effect resulting from
the demethylation of other genes regulating seladin-1
expression cannot be excluded. Additional studies should
be performed in order to determine whether the degree
of methylation may account for the different levels of
expression between normal and pathologic tissues
detected in other human organs
Conclusion
According to our results, methylation could be involved
in the altered pattern of seladin-1 gene expression in
ACC.
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